Cormorant Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Cormorant Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.7M	Sell	95,000 -5,000	-5%	-$1.12M	1.09%	26
2025 Q4	$21.3M	Buy	+100,000	New	+$20.7M	0.99%	22
2023 Q1	–	Sell	-50,000	Closed	-$6.11M	–	78
2022 Q4	$6.11M	Hold	50,000	–	–	0.41%	51
2022 Q3	$5.16M	Hold	50,000	–	–	0.36%	53
2022 Q2	$4.65M	Hold	50,000	–	–	0.35%	54
2022 Q1	$5.87M	Hold	50,000	–	–	0.45%	47
2021 Q4	$6.73M	Sell	50,000 -120,000	-71%	-$17.8M	0.4%	50
2021 Q3	$27.1M	Buy	170,000 +95,000	+127%	+$13M	1.1%	29
2021 Q2	$9.87M	Sell	75,000 -25,000	-25%	-$3.33M	0.34%	63
2021 Q1	$12.9M	Hold	100,000	–	–	0.29%	66
2020 Q4	$16.7M	Sell	100,000 -25,000	-20%	-$4.13M	0.4%	53
2020 Q3	$19.3M	Sell	125,000 -50,000	-29%	-$7.19M	0.74%	39
2020 Q2	$25.9M	Sell	175,000 -75,000	-30%	-$10.3M	0.99%	31
2020 Q1	$28.2M	Sell	250,000 -150,000	-38%	-$19.5M	1.31%	24
2019 Q4	$55.6M	Sell	400,000 -68,300	-15%	-$7.59M	2.22%	13
2019 Q3	$45.1M	Buy	468,300 +68,300	+17%	+$7.62M	2.75%	8
2019 Q2	$46.1M	Sell	400,000 -200,000	-33%	-$23.9M	2.65%	12
2019 Q1	$70.6M	Buy	600,000 +261,544	+77%	+$22.9M	4.77%	4
2018 Q4	$21.2M	Sell	338,456 -11,544	-3%	-$725K	1.72%	19
2018 Q3	$24.8M	Sell	350,000 -21,739	-6%	-$1.5M	1.61%	23
2018 Q2	$24.7M	Hold	371,739	–	–	1.83%	20
2018 Q1	$24.3M	Buy	371,739 +71,739	+24%	+$4.03M	1.81%	14
2017 Q4	$12M	Buy	+300,000	New	+$10.9M	1.26%	25
2017 Q2	–	Sell	-100,000	Closed	-$2.8M	–	72
2017 Q1	$2.8M	Sell	100,000 -62,254	-38%	-$1.57M	0.41%	53
2016 Q4	$3.28M	Buy	162,254 +100,000	+161%	+$2M	0.44%	48
2016 Q3	$1.25M	Hold	62,254	–	–	0.14%	69
2016 Q2	$826K	Buy	62,254 +754	+1%	+$11.6K	0.12%	70
2016 Q1	$1.14M	Hold	61,500	–	–	0.17%	69
2015 Q4	$1.13M	Hold	61,500	–	–	0.13%	67
2015 Q3	$1.09M	Hold	61,500	–	–	0.17%	71
2015 Q2	$1.09M	Hold	61,500	–	–	0.14%	70
2015 Q1	$1.07M	Buy	+61,500	New	+$1.12M	0.16%	61

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cormorant Asset Management's ASND Position: Q1 2026 in Review

Cormorant Asset Management reduced its Ascendis Pharma A/S (ASND) stake by 5% in Q1 2026, selling an estimated $1.12M and leaving 95,000 shares worth $21.7M. The position accounts for 1.09% of the portfolio, ranked #26.

Cormorant Asset Management first reported a position in ASND in Q1 2015 and has held it in 32 quarters since. The position peaked at $70.6M in Q1 2019. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Cormorant Asset Management held 95,000 shares of Ascendis Pharma A/S worth $21.7M as of Q1 2026.
Cormorant Asset Management sold 5,000 Ascendis Pharma A/S shares in Q1 2026, an estimated $1.12M.
Ascendis Pharma A/S made up 1.09% of Cormorant Asset Management's portfolio in Q1 2026, its #26 holding.
Cormorant Asset Management first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 32 quarters since.
Cormorant Asset Management's Ascendis Pharma A/S position peaked at $70.6M in Q1 2019.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.